

UCLA

UCLA Previously Published Works

Title

Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men.

Permalink

<https://escholarship.org/uc/item/10z8j2kw>

Journal

Scientific reports, 9(1)

ISSN

2045-2322

Authors

Cook, Ryan R
Fulcher, Jennifer A
Tobin, Nicole H
et al.

Publication Date

2019-10-01

DOI

10.1038/s41598-019-51142-8

Peer reviewed

OPEN

Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men

Ryan R. Cook¹, Jennifer A. Fulcher^{2,3}, Nicole H. Tobin⁴, Fan Li⁴, David J. Lee⁴, Cora Woodward⁴, Marjan Javanbakht¹, Ron Brookmeyer⁵, Steve Shoptaw^{6,7}, Robert Bolan^{8,9}, Grace M. Aldrovandi⁴ & Pamina M. Gorbach¹

Methamphetamine (MA) use is a major public health problem in the United States, especially among people living with HIV (PLWH). Many MA-induced neurotoxic effects are mediated by inflammation and gut microbiota may play a role in this process, yet the effects of MA on the microbiome have not been adequately explored. Therefore, we performed 16S rRNA gene sequencing on rectal swab samples from 381 men who have sex with men, 48% of whom were PLWH and 41% of whom used MA. We compared microbiome composition between MA users and non-users while testing for potential interactions with HIV and controlling for numerous confounders using inverse probability of treatment weighting. We found that MA use explained significant variation in overall composition ($R^2 = 0.005$, $p = 0.008$) and was associated with elevated *Fingoldia*, *Parvimonas*, *Peptoniphilus*, and *Porphyromonas* and reduced *Butyricoccus* and *Faecalibacterium*, among others. Genera including *Actinomyces* and *Streptobacillus* interacted with HIV status, such that they were increased in HIV+ MA users. *Fingoldia* and *Peptoniphilus* increased with increasing frequency of MA use, among others. In summary, MA use was associated with a microbial imbalance favoring pro-inflammatory bacteria, including some with neuroactive potential and others that have previously been associated with poor HIV outcomes.

The 2017 National Survey on Drug Use and Health estimated that nearly one million people in the United States were current users of methamphetamine (MA) or had a MA use disorder in the past year¹. MA use is a major public health concern with myriad negative health consequences ranging from anxiety and confusion to psychosis and violent behavior; chronic abuse may even result in severe and lasting structural changes in the brain affecting emotional regulation and cognition². MA use is much more prevalent among people living with HIV, with rates of recent use 30 times higher and rates of dependence 33 times higher than the general population (0.3% vs. 9% recent use and 0.4% vs. 13% dependence)^{1,3,4}. MA increases susceptibility to HIV infection by altering immune activity^{5,6} inhibiting neurocognitive processes involved in judgement and decision-making⁷ and increasing the frequency of risky sex acts^{4,8}. MA use among people living with HIV is associated with reduced likelihood of achieving viral suppression⁹, faster disease progression¹⁰, and increased risk of transmission to others¹¹.

Many MA-induced neurotoxic effects are mediated by inflammation^{5,12}, and the microbiome, which is involved in inducing and regulating the immune system¹³, may play a role in this process. Exposure to MA

¹Department of Epidemiology, Fielding School of Public Health at the University of California, Los Angeles, USA.

²Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, USA. ³VA Greater Los Angeles Healthcare System, Los Angeles, USA. ⁴Division of Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at the University of California, Los Angeles, USA.

⁵Department of Biostatistics, Fielding School of Public Health at the University of California, Los Angeles, USA. ⁶Department of Family Medicine, David Geffen School of Medicine at the University of California, Los Angeles, USA. ⁷Department of Psychiatry and Biobehavioral Science, David Geffen School of Medicine at the University of California, Los Angeles, USA.

⁸Los Angeles LGBT Center, Los Angeles, USA. ⁹Department of Family Medicine, Keck School of Medicine at the University of Southern California, Los Angeles, USA. Grace M. Aldrovandi and Pamina M. Gorbach jointly supervised this work. Correspondence and requests for materials should be addressed to R.R.C. (email: cookryan@ucla.edu)

impacts both innate and adaptive immunity, increasing production of inflammatory cytokines, inhibiting T-cell proliferation, altering gene expression of immune cells, modifying cytokine signaling pathways, and increasing blood-brain barrier permeability^{5,14,15}. MA damages gut wall integrity and increases intestinal permeability leading to the translocation of microbiota into the body¹⁵. This process disrupts symbiotic interactions between the host immune system and microbiota, inducing an immune response that may cyclically exacerbate intestinal permeability and further inflammation¹⁶. Microbial translocation has been cited as one of the key drivers of chronic inflammation described in many other diseases, including HIV, and may play a similar role in MA-induced inflammation and toxicity. Furthermore, mediated by inflammation, disruption of gut bacterial communities (termed “dysbiosis”) may be a mechanistic link between methamphetamine use and HIV transmission and disease progression.

Dysbiosis has been described in individuals with substance use disorders¹⁷, chronic prescription opioid¹⁸ and cocaine users¹⁹, as well as people living with HIV²⁰ and those practicing anal intercourse²¹. We recently showed that MA use was associated with microbiome changes in a small sample of HIV-infected MSM²². However, no large studies into the effects of MA on the microbiome have been completed, and no studies have examined the potential role of HIV in MA-induced dysbiosis. In order to address this gap, we studied the effects of MA on the gastrointestinal microbiome in a cohort of young men who have sex with men (MSM), approximately half of whom were HIV-infected, and all of whom were engaging in anal intercourse. We hypothesized that MA use would be associated with increased relative abundance of pro-inflammatory and pathogenic bacterial taxa as well as alterations to those with neurologic effects. We also hypothesized that MA use and HIV would interact to increase the severity of dysbiosis.

Materials and Methods

Study population. Specimens and data for this study were drawn from a larger cohort, the NIDA-funded Minority Men who have Sex with Men Cohort at UCLA Linking Infections Noting Effects (MASCULINE, or mSTUDY). Subject selection procedures have been previously described²³. Briefly, participants were all men born males, aged 18–45, with approximately one-half of the sample purposefully included due to current substance use (the other half non-substance users) and one-half of the sample purposefully included due to HIV-infection (the other half being HIV-negative). The mSTUDY was approved by the UCLA South General Institutional Review Board (IRB), and the current study was approved by the UCLA Medical IRB 1. All participants provided written informed consent prior to participation and all study procedures were done in accordance with ethical principles for human subjects research.

Specimen collection and DNA preparation. As previously described²³, samples included in this study were rectal swabs (FLOQSwabs, Copan Diagnostics, Murrieta, CA). The majority (76%) were collected via anoscopy under direct mucosal visualization and without preparatory enema at approximately 8 cm from the anal verge. Due to a protocol change, others (24%) were participant self-collected at approximately 4–5 cm from the anal verge. Collection method was taken into account in the analysis (Table 1; Supplemental content). Swabs were immediately frozen neat at -80°C until processing in bulk. For DNA processing the samples were transferred to Lysing Matrix E tubes (MP Biomedicals, Burlingame, CA) containing RLT lysis buffer (Qiagen, Hilden, Germany) and bead-beated on a TissueLyser (Qiagen). DNA was then extracted using the AllPrep DNA/RNA/Protein kit (Qiagen) per manufacturer’s protocol.

16S rRNA gene sequencing and data processing. Microbiome profiling was performed by sequencing of the V4 region of the 16S rRNA gene as previously described^{23–25}. Briefly, the V4 region was amplified in triplicate reactions using Golay-barcoded primers 515F/806R. PCR products were then pooled and sequenced on the Illumina MiSeq platform using 2×150 bp v2 chemistry. The sequences were demultiplexed with Golay error correction using QIIME v1.9.1²⁶, and Divisive Amplicon Denoising Algorithm (DADA2) version 1.8 was used for error correction, exact sequence inference, read merging, and chimera removal²⁷. The resultant amplicon sequence variant (ASV) table comprised 19,955,039 total merged read pairs (mean per sample = 52,375; range 10,906 to 124,889). Taxonomic assignment was performed using RDP trainset 16 (<https://doi.org/10.5281/zenodo.810827>). Rarefaction was performed at a depth of 10,906 reads for alpha diversity analyses. To normalize all other analyses, estimates of relative library sizes (“size factors”) were obtained by calculating geometric means of pairwise read count ratios²⁸.

Measurement of MA use. MA use was measured using an adapted version of the NIDA-modified ASSIST²⁹. Participants were asked how often they used MA in the previous six months; response choices were “Daily”, “Weekly”, “Monthly”, “Less often”, “Once”, and “Never.” For most analyses we categorized participants as MA users if they indicated any use in the past six months, and non-users if they responded “Never.” For the dose-response analysis, we combined “Monthly”, “Less often”, and “Once” into “Monthly or less often”, given that infrequent exposures are likely to have similar effects on the microbiome. In addition, participants were screened for MA use via urinalysis [Fastest® II (Branan Medical Corporation); iScreen® Dip Card (Alere)]. We did not use the urinalysis results as our primary exposure variable because the detection window for MA is 48–72 hours and no exposure quantification (and thus dose-response analysis) could be done. We instead compared the self-report and urinalysis results as a sensitivity analysis (Supplementary Figs S4, S5 and S6). HIV status was ascertained upon entry into the cohort by medical record review (for known HIV-infected participants) or the OraQuick Advance® HIV 1/2 (OraSure Technologies, Bethlehem, PA).

Behavioral and clinical covariates. Analyses controlled for a large set of behavioral and clinical covariates including age, race/ethnicity, homelessness in past six months, number of receptive anal intercourse (RAI) acts in past month, number of anal sex partners in past six months, an indicator for RAI in the past seven days, an

	MA- negative n = 225 mean (sd), median n (%)	MA-positive n = 156	P ^d	SMD ^e (pre, post IPTW)
Age	30.17 (6.85), 29	32.58 (6.75), 33	<0.001	0.35, 0.16
HIV+	80 (35.6)	102 (65.4)	<0.001	N/A
Race/ethnicity			0.6	0.1, 0.07
Black-Non Hispanic	93 (41.3)	57 (36.5)		
Hispanic	107 (47.6)	79 (50.6)		
Other-Non Hispanic	25 (11.1)	20 (12.8)		
Homeless in past 6 months	52 (23.1)	77 (49.4)	<0.001	0.57, 0.28
Had RAI in last 7 days	102 (45.3)	65 (41.7)	0.5	0.07, 0.03
Number of RAI acts in past month	2.09 (4.94), 0	2.88 (5.33), 1	<0.001	0.15, 0.03
Number of anal sex partners in past 6 months	6.17 (7.60), 3	8.79 (9.28), 5	<0.001	0.31, 0.18
Positive for STI ^a	19 (8.4)	28 (17.9)	0.006	0.28, 0.18
Marijuana use in past 6 months			0.1	0.23, 0.21
Daily/Weekly	69 (30.7)	60 (38.5)		
Monthly/less	52 (23.1)	41 (26.3)		
Never	104 (46.2)	55 (35.3)		
Cocaine use in past 6 months	40 (17.8)	60 (38.5)	<0.001	0.47, 0.24
Tobacco smoker	73 (32.4)	95 (60.9)	<0.001	0.6, 0.38
Binge drinking in past 6 months ^b	138 (61.3)	91 (58.3)	0.6	0.06, 0.04
Antibiotic use in past month	15 (6.7)	16 (10.3)	0.2	0.13, 0.07
Sample collection strategy			0.5	0.07, 0.01
Anoscopy	169 (75.1)	122 (78.2)		
Self-collected	56 (24.9)	34 (21.8)		
Type of ART			<0.001	0.56, 0.28
INSTI + NRTI	30 (13.3)	39 (25.0)		
NNRTI + NRTI	25 (11.1)	23 (14.7)		
NRTI + PI	15 (6.7)	15 (9.6)		
Other	4 (1.8)	12 (7.7)		
HIV+ and missing ART data	6 (2.7)	14 (9.0)		
HIV – pre-exposure prophylaxis (PrEP) user	30 (13.3)	7 (4.5)		
HIV –, no PrEP	115 (51.1)	47 (30.1)		
Among HIV+ participants only				
HIV RNA log ₁₀ copies/mL (median, IQR) ^c	1.03 (0.7)	1.03 (1.7)		N/A
CD4 cells/mm ³ (median, IQR) ^c	590.5 (267)	635 (424.3)		N/A
CD4 cells/mm ³ <200	5 (2.2)	9 (5.8)		0.18, 0.15

Table 1. Participant characteristics, N = 381 men who have sex with men in Los Angeles, CA.

MA = Methamphetamine; SMD = Standardized mean difference; RAI = Receptive anal intercourse; STI = Sexually transmitted infection; ART = Antiretroviral therapy; INSTI = Integrase strand transfer inhibitor; NRTI = Nucleoside reverse transcriptase inhibitor; NNRTI = Non-nucleoside reverse transcriptase inhibitor; PI = Protease inhibitor. ^aSexually transmitted infections include rectal gonorrhea, rectal chlamydia as well as primary/secondary syphilis. ^bBinge drinking defined as 6 or more drinks on one occasion. ^cHIV status, HIV RNA, and continuous CD4 cell count were not included in the inverse probability of treatment weight model, all other variables in the table were included. HIV status was taken into account in the analyses by stratifying on it (if there was evidence for an interaction between MA and HIV) or conditioning on it (if there was no evidence for an interaction). ^dp values are from Wilcoxon tests or Chi-square tests. ^eSMD is a measure of imbalance across groups; higher SMDs indicate greater imbalance. Average SMD before weighting = 0.28, after weighting = 0.14.

indicator for a positive STI test (including PCR tests for rectal gonorrhea and chlamydia and serology for primary or secondary syphilis), self-reported use of marijuana and cocaine, tobacco smoking, and binge drinking (defined as 6+ drinks on more than one occasion) in the past six months, and use of antibiotics in the past month. We also controlled for type of antiretroviral therapy (including use of pre-exposure prophylaxis if HIV –) and an indicator for CD4 cell count <200 (Table 1). Measures and assays have been previously described²³.

Statistical analyses. We compared clinical and behavioral characteristics between MA users and non-users using descriptive statistics, Wilcoxon or Chi-square tests, and standardized mean differences (see Table 1; Supplemental content). All analyses of microbiome outcomes were adjusted for clinical and behavioral confounders using inverse probability of treatment weighting (IPTW). IPTW is a technique in which the study sample is re-weighted to achieve balance between exposure groups (here, MA users vs. non-users) on important covariates so that their confounding effects are substantially reduced³⁰. Covariates included in the IPTW model are listed in Table 1, and further information about the IPTW calculation and adjustment process is available in the

supplemental content as well as our previous publication²³. Weights were estimated using generalized boosted models (R package ‘twang’³¹) and robust standard errors for IPTW-adjusted analyses were obtained using the sandwich estimator (R package ‘sandwich’³²). All analyses in this study proceeded by first testing for interactions between MA use and HIV status using multiplicative interaction terms. An alpha level of 0.1 was used as a cutoff for significance of interaction tests; if significant, comparisons of MA users vs. non-users are presented stratified by HIV status (retaining HIV status and the interaction term in the model). If no significant interaction was detected, comparisons of MA users vs. non-users were completed controlling for HIV status (retaining HIV status as a covariate but dropping the interaction term).

The R package ‘phyloseq’³³ was used to calculate distance matrices, alpha diversity metrics, and for ordination. Permutational multivariate ANOVA (PERMANOVA; R package ‘vegan’³⁴) was used to test for differences in overall microbial composition. Cluster analysis was performed using the partitioning around medoids method with the optimal number of clusters chosen according to the Calinski-Harabasz statistic (R packages ‘cluster’³⁵ and ‘fpc’³⁶). Logistic regression was used to assess the relationship between MA use and cluster membership. Linear regression was used to test for differences in alpha diversity between MA users and non-users. Zero-inflated negative binomial (ZINB) models were used to test for differences in individual bacterial genera between groups (R package ‘pscl’³⁷). We employed a previously described model selection strategy²³ to choose the optimal ZINB model for each genus. A pre-filtering step excluded genera appearing in less than 10% of samples as well as those with less than 100 total reads across all samples, resulting in 78 genera included in ZINB analyses. Dose-response analysis was completed by regressing bacterial counts on frequency of MA use using orthogonal polynomial coding of linear and quadratic curves. As sensitivity analyses, all analyses were repeated redefining MA use according to urine drug screen results (except for dose-response, owing to the qualitative nature of urine drug screening). Finally, we examined short-term interactions between MA use and the microbiome using a correlation analysis among individuals testing positive for MA on urine drug screen. Correlations were calculated with the sparCC method³⁸ with bootstrapped standard errors (R package ‘SpiecEasi’³⁹).

PERMANOVA, alpha diversity, and dose-response analyses utilized a threshold of $p < 0.05$ to determine statistical significance. In order to account for the large amount of genera tested, p values obtained in ZINB analyses and sparCC correlations were corrected using Benjamini & Hochberg’s False Discovery Rate (FDR) method⁴⁰. FDR-adjusted p values are labelled as q values, and $q < 0.1$ was used as a threshold to determine statistical significance. Accordingly, we display 90% false coverage rate (FCR)-adjusted confidence intervals⁴¹ to accompany these analyses. All statistical analyses were performed using R v.3.5.1⁴² and graphics were generated with ggplot2⁴³.

Results

Participant characteristics. This study included 381 participants, 156 MA users (41%) and 225 non-users (59%). All participants were MSM, the mean age was 31, and most were Hispanic (49%) or non-Hispanic Black (39%). One hundred eighty-two participants were HIV+ (48%); sixty-five percent of MA users were HIV+ as compared to 36% of non-users. MA users were also older than non-users, were more likely to have experienced homelessness, had RAI more frequently, had more anal sex partners, were more likely to have recently used cocaine, and were more likely to be tobacco smokers (Table 1).

Effects of MA use on overall microbial composition and diversity. PERMANOVA analyses with Bray-Curtis, Jaccard, and Jensen-Shannon distances did not reveal significant evidence supporting an interaction between MA and HIV on overall microbial composition (all $p > 0.1$; interaction p values supplied in Supplementary Table S1). Therefore, we described and compared overall composition between MA users and non-users while controlling for HIV status. Qualitative examination of descriptive barplots suggested increased *Finegoldia*, *Fusobacterium*, *Peptoniphilus*, *Porphyromonas*, *Streptobacillus*, and *Streptococcus* and decreased *Bacteroides*, *Faecalibacterium*, and *Succinivibrio* in MA users compared to non-users (Fig. 1A,B). Ordination of Bray-Curtis, Jaccard, and Jensen-Shannon distances by principal coordinates analyses revealed clustering by MA status (Fig. 2A). These findings were supported by PERMANOVA analyses showing that MA explained significant variation in overall microbial composition (Bray-Curtis $R^2 = 0.005$, $p = 0.008$; additional results in Fig. 2A). Additionally, a clustering analysis using partitioning around medoids of Bray-Curtis distances revealed two distinct clusters in the microbiome data, which were significantly related to MA use. Adjusted for HIV status and our behavioral and clinical covariate set, the likelihood of classification into the second cluster was 2.24 times higher for MA users compared to non-users (OR = 2.24, $p = 0.011$, pseudo- $R^2 = 0.008$).

No significant interactions between MA and HIV were detected in observed diversity or Chao1, Shannon, or Simpson indices (all $p > 0.1$; Supplementary Table S1), and no differences in diversity were detected between MA users and non-users in any metric (Fig. 2B). Despite lack of evidence for an interaction between HIV and MA use, we display descriptive, ordination and alpha diversity plots stratified by HIV status in Supplementary Figs S1 and S2.

Effects of MA use on specific genera. Using ZINB models with IPTW adjustment, we found differences between MA users and non-users in multiple genera. For some, there was no evidence for an interaction between MA and HIV: Regardless of HIV status, MA users had higher levels of *Finegoldia*, *Fusobacterium*, *Parvimonas*, *Peptoniphilus*, *Peptostreptococcus*, and *Porphyromonas*, and lower levels of *Butyrivibrio* and *Faecalibacterium*, among others (all $q < 0.1$; Fig. 3; estimates and q values supplied in Supplementary Table S2). For four genera, a significant ($q < 0.1$; interaction q values supplied in Supplementary Table S2) interaction between HIV and MA was detected. *Actinomyces*, *Mannheimia*, *Negativicoccus*, and *Streptobacillus* were increased in HIV+ MA users compared to HIV+ non-users, but no difference was found in the absence of HIV. No genera were significant only in the HIV– stratum.




Figure 1. Rectal microbial composition of study participants, N = 381. (A) Columns represent the relative composition of each subject's microbiome at the genus level. Methamphetamine (MA) use by the subjects is indicated by a colored line below their composition. Subjects are ordered by the first principal coordinate of a Bray-Curtis pairwise distance matrix. Genera representing less than 1% of the composition on average across samples were combined into "Other." (B) Average microbial composition within each MA use group. Bacterial genera representing less than 1% of the overall relative composition or present in less than 10% of the samples were grouped into "Other."

Dose-response analysis of bacterial counts on increasing frequency of MA use. Of the 156 MA users in the study, 40 were daily users, 35 used weekly, and 81 used monthly or less often. Counts of *Anaerococcus*, *Corynebacterium*, *Dietzia*, *Finegoldia*, *Mannheimia* and *Peptoniphilus* increased linearly with increasing frequency of MA use ($q < 0.1$ for test of linear trend). No significant quadratic dose-response curves were noted in any genera (Fig. S3).

Sensitivity analysis using urine toxicology screening to define MA use. Our findings, which were based on participant self-report of MA use, were consistent when we re-defined MA use using urine drug screening results. All participants completed urine drug screening, and fourteen percent of study participants ($n = 52$) tested positive for MA including 3 individuals who self-reported no MA use (49/52 who tested positive also self-reported using MA). One hundred seven self-reported using MA, but tested negative, likely because their last use was outside the drug screen window of detection. HIV+ participants were more likely to have a positive MA urine drug screen (21% among HIV+ vs. 7% among HIV-, $p < 0.001$).

In biomarker analyses, MA use was still a significant driver of variation in overall microbial composition (Bray-Curtis $R^2 = 0.008$, $p = 0.008$), and no differences in alpha diversity were noted between MA users and non-users. Many of the same genera were elevated in MA users, e.g., *Finegoldia*, *Fusobacterium*, *Peptoniphilus*, *Peptostreptococcus*, and *Porphyromonas*, and elevations in *Streptobacillus* in the HIV+ stratum were noted in both analyses. Depletion in *Faecalibacterium* was consistent across analyses; the biomarker analysis also identified depletions in *Clostridium* cluster XI and *Lactobacillus* in MA users. Results from this sensitivity analysis are presented in Supplementary Figs S4–S6.




Figure 2. Associations between methamphetamine (MA) use and overall microbial composition and diversity. **(A)** Ordination of the samples using principal coordinates analysis. PCoA = Principal coordinate axis. Ellipses are 95% confidence regions for each group assuming points follow a multivariate t distribution. R^2 and p values are from PERMANOVA analyses of distance metrics. **(B)** Boxplots of diversity metrics. Boxes represent the inverse probability of treatment weight-adjusted lower, median, and upper quartiles of the data and whiskers are 1.5*interquartile range. p values are from IPTW-adjusted linear regression analyses comparing diversity metrics between MA users and non-users.

Finally, to examine short-term interactions between MA use and the microbiome, we performed a general correlation analysis among individuals testing positive for recent MA use. Large, significant positive correlations were noted between *Parvimonas* and *Campylobacter* as well as *Peptoniphilus* and *Campylobacter*, among others (sparCC correlation >0.6 and $q < 0.1$). Moderate-to-large negative correlations were noted between *Alloprevotella* and *Butyricoccus* as well as *Parabacteroides* and *Campylobacter*, among others (sparCC correlation < -0.4 and $q < 0.1$). Full results are presented in Supplemental Table S3 and Fig. S7.

Discussion

This study of 381 MSM who were either HIV-infected or at high risk for HIV acquisition found that MA use significantly impacted gut microbial composition after controlling for multiple clinical and behavioral confounders. Measures of overall composition were altered by MA use, but measures of diversity were not, and the associations between MA and overall composition and diversity did not depend on participants' HIV status. Several genera were increased in MA users regardless of HIV status, many of them considered pro-inflammatory and pathogenic, while others were increased among HIV+ participants only. We found that the abundance of some pro-inflammatory taxa increased and commensals decreased with increasing frequency of MA use. Finally, we were able to replicate our findings using a biomarker confirming recent MA use (urine drug screen). MA effect sizes were slightly larger in the biomarker analysis, likely because the window of detection for MA is short, making frequent users more likely to test positive. Our analyses utilized a novel method of confounder control, IPTW,




Figure 3. Comparisons of individual genera between methamphetamine (MA) users and non-users. Forest plots of results of zero-inflated negative binomial models comparing genus-level bacterial counts between methamphetamine (MA) users and non-users. Inverse probability of treatment-weighted effect sizes (log normalized count ratios) and false coverage rate (FCR)-adjusted 90% confidence intervals are plotted, with statistical significance ($q < 0.1$) indicated in black. Genera with no effect are not shown. Dots are sized proportionally to overall mean abundance across samples, i.e., genera with larger dots are, on average, more abundant.

to account for several factors that have previously been associated with dysbiosis (e.g. RAI²¹, cocaine use¹⁹, and alcohol use⁴⁴), making our findings more likely to be truly attributable to MA use.

Although little research has been done on the effects of MA on the microbiome, our results are mostly consistent with previously published literature. A study of 37 HIV+ individuals from the same cohort as the current data²² (none of the individuals in this current sample were included in the previous study) reported a MA effect size (PERMANOVA R^2) of 0.1, larger than the effect we found. As in our study, there were no significant differences in diversity between MA users and non-users. Enrichment in *Porphyromonas* in MA users was consistent across studies. As a well-known modifier of inflammatory cytokines and a potential cause of intestinal permeability⁴⁵, *Porphyromonas* may play a role in MA-associated inflammation and deserves further investigation. Another study in which MA was administered to rats reported an overall effect of MA that is consistent with our findings (R^2 of 0.008)⁴⁶. This study also reported higher alpha diversity in the MA-conditioned group, which was not replicated in our study, and taxonomic differences that do not overlap with our findings, likely because of differences between the mouse model and a human cohort. Finally, a study comparing individuals with substance use disorders (SUDs) to healthy controls found a large effect of SUD (R^2 of 0.067), higher observed diversity among individuals with SUDs, and differences in specific genera that do not match our findings¹⁷. However, participants with MA use disorder only accounted for 30% of the SUD group, and the study did not control for large differences in lifestyle and clinical confounders between individuals with SUDs and healthy controls.

MA use is associated with increases in production and alterations in gene expression of many pro-inflammatory cytokines^{6,47}, which may contribute to neurological deficits, anxiety, and impaired memory⁴⁸. Many of the bacterial genera that were elevated in MA users, such as *Porphyromonas*⁴⁵, *Veillonella*⁴⁹, and *Fusobacterium*⁵⁰ have been correlated with increases in pro-inflammatory cytokines. MA also exacerbates systemic inflammation by damaging gastrointestinal barrier integrity and inducing permeability, allowing the translocation of microbes and microbial products into the body. Our study identified depletions in the butyrate-producing genera *Faecalibacterium* and *Butyricoccus* in MA users, which have been inversely

correlated with biomarkers of microbial translocation^{51,52}. A study of patients with alcohol use disorder showed that those with higher levels of gut permeability had lower levels of *Bifidobacterium* and *Faecalibacterium* species and exhibited more symptoms of alcohol dependence and cravings⁵³.

Emerging preclinical research has demonstrated a complex interplay between the microbiome and the central nervous system⁵⁴, leading to inquiries about the role of dysbiosis in addiction pathology. Gut bacteria produce neuroactive substances, including serotonin, epinephrine and dopamine⁵⁵, which may access the brain's reward centers via gut-innervating vagal neurons⁵⁶. *Streptococcus*, which was elevated in MA users in our study, can produce serotonin and *Lactobacillus*, which was depleted in MA users (in our biomarker analysis), can produce gamma-aminobutyric acid (GABA)⁵⁵. Laboratory experiments of other drugs of abuse have suggested a connection between dysbiosis and addiction pathology. For example, increased sensitivity to cocaine reward through alterations in dopaminergic pathways has been observed in mice with experimentally disrupted microbiome⁵⁷. Another study showed that manipulation of the microbiome resulted in several characteristics of opioid dependence in mice, such as reduced opioid analgesic potency and impaired reward behavior⁵⁸. In addition, there is some preclinical evidence that “repairing” the microbiome might alleviate addiction pathology, e.g., *Lactobacillus* species restored chemically-depressed dopamine levels in the prefrontal cortex when administered to rats as a probiotic⁵⁹. However, these studies have not involved MA, and the preclinical connection between dysbiosis and MA dependence is speculative.

In humans, potential mechanisms linking dysbiosis to the pathology of MA dependence remain largely unexplored. There is limited clinical evidence linking dysbiosis with symptoms associated with MA dependence, such as altered stress response and increased depression. Butyrate-producing *Faecalibacterium*, which was decreased in MA users in our study, has been associated with reduced depression and higher quality of life⁶⁰. Common symptoms of MA withdrawal, including depression, anxiety, and fatigue, have been correlated with imbalances in gut microbiota⁶¹, and probiotics have been used to successfully reduce anxiety and depression in clinical trials⁶². It is plausible that targeting dysbiosis may ease these symptoms among individuals undergoing treatment for MA use disorders.

We also found a number of genera that were impacted by MA which have previously been shown to play a role in HIV acquisition, disease progression, and pathogenesis. Increased abundances of *Finegoldia* and *Peptoniphilus* in the penile microbiome have been associated with elevated risk for HIV seroconversion in men⁶³, and *Parvimonas* has been shown to increase genital tract inflammation⁶⁴ and the risk of HIV acquisition in women⁶⁵. The implications of enrichment of these bacteria in the rectal microbiome have not been explored; however, it is likely that inflammation exacerbated by dysbiosis underlies the increase in seroconversion risk, which would be highly relevant to at-risk MSM. We also found that MA use increased *Fusobacterium*, which has been correlated with decreased CD4+ T-cell count and increased T-cell activation in HIV+ individuals as well as reduced T-cell recovery following ART initiation⁶⁶. HIV and MA interacted to multiplicatively increase *Actinomyces*, which may play a role in reactivating HIV in latently infected cells⁶⁷. *Parvimonas* and *Peptostreptococcus* are oral pathogens that have been implicated in periodontal infections among HIV+ individuals^{68,69}, and their damaging effects may be heightened in MA users due to MA's proclivity to reduce saliva production. Finally, increased abundance of *Veillonella* has been linked with HIV-associated pulmonary diseases⁷⁰. Our study, showing that MA impacted the relative abundance of each of these genera, may highlight mechanisms underlying the relationship between MA use, HIV acquisition and transmission risk, and HIV disease progression which warrant further investigation.

Our results should be interpreted considering the following limitations. Primarily, no diet data is collected for this cohort. We controlled for race/ethnicity and homelessness, which may impact diet and thus mitigate the effects of this limitation; however, we were unable to fully account for the effects of diet in our analyses. Using IPTW, our study accounts for a plethora of other clinical and behavioral confounders which may have masked true findings or generated spurious associations in previous studies. However, IPTW cannot achieve perfect balance between exposure groups in real-world research applications, and thus we cannot rule out residual confounding even by variables included in our analyses. Our study was also conducted in a cohort comprised entirely of MSM, all of whom were practicing anal intercourse, which increases internal validity by eliminating the effects of some important confounders (e.g. gender, sexual behavior). However, this may limit the generalizability of our findings to other groups, such as women who use MA. Finally, because the ability of 16S gene sequencing to identify bacterial species is limited, we conducted our analyses at the genus level. We caution that differences in genera do not necessarily correspond to differences in functionally important species.

MA use remains a significant public health challenge, especially among people living with HIV. Our study found that MA use was associated with an imbalance in gut microbial composition favoring pro-inflammatory, potentially pathogenic bacteria, including some with neuroactive potential. There is currently no accepted pharmaceutical treatment for MA use disorder and limited evidence for the effectiveness of cognitive-behavioral therapy; further research into changes in the microbiome associated with MA use may inform therapeutic approaches for individuals with MA use disorder. Moreover, increases in multiple taxa that have been previously associated with poor HIV outcomes or HIV transmission and acquisition are particularly concerning in our study population of MSM who were either HIV-infected or at high risk for infection. Additional investigation into the mechanisms underlying these associations may improve HIV prognosis and prevent future infections among this vulnerable group.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. All sequencing data has been deposited into BioProject with the accession number PRJNA422134.

References

1. Substance Abuse and Mental Health Services Administration. *Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health*, <https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf> (2018).
2. National Institute on Drug Abuse. *Research Report Series: Methamphetamine*, <https://d14rmgrtwzf5a.cloudfront.net/sites/default/files/methrrs.pdf> (2013).
3. Hartzler, B. *et al.* Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. *AIDS Behav* **21**, 1138–1148, <https://doi.org/10.1007/s10461-016-1584-6> (2017).
4. Mimiaga, M. J. *et al.* Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. *American journal of public health* **103**, 1457–1467, <https://doi.org/10.2105/ajph.2012.301162> (2013).
5. Salama, S. A., Sorrentino, E. E., Nosanchuk, J. D. & Martinez, L. R. Impact of methamphetamine on infection and immunity. *Frontiers in neuroscience* **8**, 445, <https://doi.org/10.3389/fnins.2014.00445> (2014).
6. Fulcher, J. A. *et al.* Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus. *Journal of acquired immune deficiency syndromes (1999)* **78**, 119–123, <https://doi.org/10.1097/qai.0000000000001643> (2018).
7. Drouman, V. *et al.* Neurocognitive decision-making processes of casual methamphetamine users. *NeuroImage. Clinical*, 101643, <https://doi.org/10.1016/j.nicl.2018.101643> (2018).
8. Maxwell, S., Shahmanesh, M. & Gafos, M. Chemsex behaviours among men who have sex with men: A systematic review of the literature. *The International journal on drug policy* **63**, 74–89, <https://doi.org/10.1016/j.drugpo.2018.11.014> (2018).
9. Hood, J. E. *et al.* The Changing Burden of HIV Attributable to Methamphetamine Among Men Who Have Sex with Men in King County, Washington. *AIDS Patient Care STDS* **32**, 223–233, <https://doi.org/10.1089/apc.2017.0306> (2018).
10. Carrico, A. W. *et al.* Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. *Journal of acquired immune deficiency syndromes (1999)* **67**, 508–513, <https://doi.org/10.1097/qai.0000000000000364> (2014).
11. Scott, H. M. *et al.* Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States. *Journal of acquired immune deficiency syndromes (1999)* **65**, 115–121, <https://doi.org/10.1097/QAI.0b013e3182a98bae> (2014).
12. Loftis, J. M. & Janowsky, A. Neuroimmune basis of methamphetamine toxicity. *International review of neurobiology* **118**, 165–197, <https://doi.org/10.1016/b978-0-12-801284-0.00007-5> (2014).
13. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. *Cell* **157**, 121–141, <https://doi.org/10.1016/j.cell.2014.03.011> (2014).
14. Potluri, R., Haldar, B., Cenna, J. M., Sriram, U. & Fan, S. Methamphetamine alters T cell cycle entry and progression: role in immune dysfunction. *Cell death discovery* **4**, 44, <https://doi.org/10.1038/s41420-018-0045-6> (2018).
15. Prakash, M. D. *et al.* Methamphetamine: Effects on the brain, gut and immune system. *Pharmacological research* **120**, 60–67, <https://doi.org/10.1016/j.phrs.2017.03.009> (2017).
16. Branchley, J. M. & Douek, D. C. Microbial translocation across the GI tract. *Annual review of immunology* **30**, 149–173, <https://doi.org/10.1146/annurev-immunol-020711-075001> (2012).
17. Xu, Y. *et al.* Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing. *Scientific reports* **7**, 3628, <https://doi.org/10.1038/s41598-017-03706-9> (2017).
18. Banerjee, S. *et al.* Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. *Mucosal immunology* **9**, 1418–1428, <https://doi.org/10.1038/mi.2016.9> (2016).
19. Volpe, G. E. *et al.* Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation. *Journal of studies on alcohol and drugs* **75**, 347–357 (2014).
20. Dillon, S. M., Frank, D. N. & Wilson, C. C. The gut microbiome and HIV-1 pathogenesis: a two-way street. *AIDS (London, England)* **30**, 2737–2751, <https://doi.org/10.1097/qad.0000000000001289> (2016).
21. Noguera-Julian, M. *et al.* Gut Microbiota Linked to Sexual Preference and HIV Infection. *EBioMedicine* **5**, 135–146, <https://doi.org/10.1016/j.ebiom.2016.01.032> (2016).
22. Fulcher, J. A. *et al.* Effects of Substance Use and Sex Practices on the Intestinal Microbiome During HIV-1 Infection. *The Journal of infectious diseases* **218**, 1560–1570, <https://doi.org/10.1093/infdis/jiy349> (2018).
23. Cook, R. R. *et al.* Effects of HIV viremia on the gastrointestinal microbiome of young MSM. *AIDS (London, England)* **33**, 793–804, <https://doi.org/10.1097/qad.0000000000002132> (2019).
24. Bender, J. M. *et al.* Maternal HIV infection influences the microbiome of HIV-uninfected infants. *Science translational medicine* **8**, 349ra100, <https://doi.org/10.1126/scitranslmed.aaf5103> (2016).
25. Pannaraj, P. S. *et al.* Shared and Distinct Features of Human Milk and Infant Stool Viromes. *Frontiers in microbiology* **9**, 1162, <https://doi.org/10.3389/fmicb.2018.01162> (2018).
26. Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nature methods* **7**, 335–336, <https://doi.org/10.1038/nmeth.f.303> (2010).
27. Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina amplicon data. *Nature methods* **13**, 581–583, <https://doi.org/10.1038/nmeth.3869> (2016).
28. Chen, L. *et al.* GMPR: A robust normalization method for zero-inflated count data with application to microbiome sequencing data. *PeerJ* **6**, e4600, <https://doi.org/10.7717/peerj.4600> (2018).
29. National Institute on Drug Abuse. *NIDA-Modified ASSIST V2.0*, <https://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf> (2012).
30. Robins, J. M., Hernan, M. A. & Brumback, B. Marginal structural models and causal inference in epidemiology. *Epidemiology (Cambridge, Mass.)* **11**, 550–560 (2000).
31. Ridgeway, D., McCaffrey, D. F., Morral, A., Griffin, B. A. & Burgette, L. F. Toolkit for Weighting and Analysis of Nonequivalent Groups v. R package version 1.5, <https://CRAN.R-project.org/package=twang> (2017).
32. Zeileis, A. Econometric Computing with HC and HAC Covariance Matrix Estimators. *Journal of statistical software* **1** (2004).
33. McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS one* **8**, e61217, <https://doi.org/10.1371/journal.pone.0061217> (2013).
34. Oksanen, J. *et al.* vegan: Community Ecology Package v. R package version 2.5-4, <https://CRAN.R-project.org/package=vegan> (2019).
35. Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M. & Hornik, K. cluster: Cluster Analysis Basics and Extensions v. R package version 2.1.0, <https://CRAN.R-project.org/package=cluster> (2019).
36. Hennig, C. fpc: Flexible Procedures for Clustering v. R package version 2.2-3, <https://CRAN.R-project.org/package=fpc> (2019).
37. Zeileis, A., Kleiber, C. & Jackman, S. Regression Models for Count Data in R. *Journal of statistical software* **1** (2008).
38. Friedman, J. & Alm, E. J. Inferring Correlation Networks from Genomic Survey Data. *PLoS computational biology* **8**, e1002687, <https://doi.org/10.1371/journal.pcbi.1002687> (2012).
39. Kurtz, Z. D. *et al.* Sparse and Compositionally Robust Inference of Microbial Ecological Networks. *PLoS computational biology* **11**, e1004226, <https://doi.org/10.1371/journal.pcbi.1004226> (2015).

40. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the royal statistical society. Series B (Methodological)*, 289–300 (1995).
41. Benjamini, Y. & Yekutieli, D. False Discovery Rate-Adjusted Multiple Confidence Intervals for Selected Parameters. *Journal of the American Statistical Association* **100**, 71–81, <https://doi.org/10.1198/016214504000001907> (2005).
42. R Core Team R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2018), <https://www.R-project.org/>.
43. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*. (Springer-Verlag, 2016).
44. Mutlu, E. A. *et al.* Colonic microbiome is altered in alcoholism. *American journal of physiology. Gastrointestinal and liver physiology* **302**, G966–978, <https://doi.org/10.1152/ajpgi.00380.2011> (2012).
45. Nakajima, M. *et al.* Oral Administration of *P. gingivalis* Induces Dysbiosis of Gut Microbiota and Impaired Barrier Function Leading to Dissemination of Enterobacteria to the Liver. *PLoS one* **10**, e0134234, <https://doi.org/10.1371/journal.pone.0134234> (2015).
46. Ning, T., Gong, X., Xie, L. & Ma, B. Gut Microbiota Analysis in Rats with Methamphetamine-Induced Conditioned Place Preference. *Frontiers in microbiology* **8**, 1620, <https://doi.org/10.3389/fmicb.2017.01620> (2017).
47. Li, X. *et al.* Methamphetamine causes neurotoxicity by promoting polarization of macrophages and inflammatory response. *Human & experimental toxicology* **37**, 486–495, <https://doi.org/10.1177/0960327117714039> (2018).
48. Grigoleit, J. S. *et al.* Dose-dependent effects of endotoxin on neurobehavioral functions in humans. *PLoS one* **6**, e28330, <https://doi.org/10.1371/journal.pone.0028330> (2011).
49. Abe, K. *et al.* Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. *PLoS one* **13**, e0198757, <https://doi.org/10.1371/journal.pone.0198757> (2018).
50. Proenca, M. A. *et al.* Relationship between *Fusobacterium nucleatum*, inflammatory mediators and microRNAs in colorectal carcinogenesis. *World journal of gastroenterology* **24**, 5351–5365, <https://doi.org/10.3748/wjg.v24.i47.5351> (2018).
51. Dillon, S. M. *et al.* Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. *AIDS (London, England)* **31**, 511–521, <https://doi.org/10.1097/qad.0000000000001366> (2017).
52. Mutlu, E. A. *et al.* A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. *PLoS pathogens* **10**, e1003829, <https://doi.org/10.1371/journal.ppat.1003829> (2014).
53. Leclercq, S. *et al.* Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proc Natl Acad Sci USA* **111**, E4485–4493, <https://doi.org/10.1073/pnas.1415174111> (2014).
54. Burokas, A., Moloney, R. D., Dinan, T. G. & Cryan, J. F. Microbiota regulation of the Mammalian gut-brain axis. *Advances in applied microbiology* **91**, 1–62, <https://doi.org/10.1016/bs.aambs.2015.02.001> (2015).
55. Cryan, J. F. & Dinan, T. G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nature reviews. Neuroscience* **13**, 701–712, <https://doi.org/10.1038/nrn3346> (2012).
56. Han, W. *et al.* A Neural Circuit for Gut-Induced Reward. *Cell* **175**, 665–678.e623, <https://doi.org/10.1016/j.cell.2018.08.049> (2018).
57. Kiraly, D. D. *et al.* Alterations of the Host Microbiome Affect Behavioral Responses to Cocaine. *Scientific reports* **6**, 35455, <https://doi.org/10.1038/srep35455> (2016).
58. Lee, K. *et al.* The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology* **43**, 2606–2614, <https://doi.org/10.1038/s41386-018-0211-9> (2018).
59. Wei, C. L. *et al.* Antidepressant-like activities of live and heat-killed *Lactobacillus paracasei* PS23 in chronic corticosterone-treated mice and possible mechanisms. *Brain research*, <https://doi.org/10.1016/j.brainres.2019.01.025> (2019).
60. Valles-Colomer, M. *et al.* The neuroactive potential of the human gut microbiota in quality of life and depression. *Nature Microbiology*, <https://doi.org/10.1038/s41564-018-0337-x> (2019).
61. Stevens, B. R. *et al.* Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. *Gut* **67**, 1555–1557, <https://doi.org/10.1136/gutjnl-2017-314759> (2018).
62. Pirbaglou, M. *et al.* Probiotic supplementation can positively affect anxiety and depressive symptoms: a systematic review of randomized controlled trials. *Nutrition research (New York, N.Y.)* **36**, 889–898, <https://doi.org/10.1016/j.nutres.2016.06.009> (2016).
63. Liu, C. M. *et al.* Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection. *mBio* **8**, <https://doi.org/10.1128/mBio.00996-17> (2017).
64. Lennard, K. *et al.* Microbial Composition Predicts Genital Tract Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. *Infection and immunity* **86**, <https://doi.org/10.1128/iai.00410-17> (2018).
65. McClelland, R. S. *et al.* Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. *The Lancet. Infectious diseases* **18**, 554–564, [https://doi.org/10.1016/s1473-3099\(18\)30058-6](https://doi.org/10.1016/s1473-3099(18)30058-6) (2018).
66. Lee, S. C. *et al.* Enrichment of gut-derived *Fusobacterium* is associated with suboptimal immune recovery in HIV-infected individuals. *Scientific reports* **8**, 14277, <https://doi.org/10.1038/s41598-018-32585-x> (2018).
67. Huang, C. B., Emerson, K. A., Gonzalez, O. A. & Ebersole, J. L. Oral bacteria induce a differential activation of human immunodeficiency virus-1 promoter in T cells, macrophages and dendritic cells. *Oral microbiology and immunology* **24**, 401–407, <https://doi.org/10.1111/j.1399-302X.2009.00533.x> (2009).
68. Brito, L. C. *et al.* Microbiologic profile of endodontic infections from HIV– and HIV+ patients using multiple-displacement amplification and checkerboard DNA-DNA hybridization. *Oral diseases* **18**, 558–567, <https://doi.org/10.1111/j.1601-0825.2012.01908.x> (2012).
69. Paster, B. J. *et al.* Bacterial diversity in necrotizing ulcerative periodontitis in HIV-positive subjects. *Annals of periodontology* **7**, 8–16, <https://doi.org/10.1902/annals.2002.7.1.8> (2002).
70. Shenoy, M. K. & Lynch, S. V. Role of the lung microbiome in HIV pathogenesis. *Current opinion in HIV and AIDS* **13**, 45–52, <https://doi.org/10.1097/coh.0000000000000427> (2018).

Acknowledgements

This work was supported by the National Institute on Drug Abuse (1R36 DA046310 and 2U01 DA036267) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS; National Institute of Mental Health P30 MH58107). Additional support provided by the UCLA AIDS Institute and UCLA CFAR Microbiome and Mucosal Immunology Core (P30 AI028697). J.A.F. was supported in part by National Institute of Allergy and Infectious Diseases (NIAID) (K08 AI124979). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author Contributions

R.R.C., J.F., N.H.T., F.L., M.J., R. Brookmeyer, G.M.A. and P.M.G. were responsible for the study concept and design. S.S., R. Bolan, and P.M.G. were instrumental in data and sample acquisition and J.F., N.H.T., C.W. and G.M.A. performed the 16S gene sequencing. F.L. and D.L. performed the bioinformatic and genomic analyses, R.R.C. and R. Brookmeyer performed the statistical analyses, and all authors assisted with interpretation of the results. R.R.C. drafted the manuscript and J.F., N.H.T., F.L., M.J., R. Brookmeyer, S.S., G.M.A. and P.M.G. provided critical revision of the manuscript for important intellectual content. All authors critically reviewed content and approved the final version for publication.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-51142-8>.

Competing Interests: Dr. Steve Shoptaw declares that he has received supplies for clinical trials from Pfizer and Medicinova.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019